You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Medtronic
Dow
Harvard Business School
Moodys

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

Supernus Pharms Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for SUPERNUS PHARMS, and what generic alternatives to SUPERNUS PHARMS drugs are available?

SUPERNUS PHARMS has two approved drugs.

There are nineteen US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.

There are twenty-five patent family members on SUPERNUS PHARMS drugs in ten countries and one supplementary protection certificate in one country.

Summary for Supernus Pharms
International Patents:25
US Patents:19
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Supernus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No 8,298,576   Start Trial Y   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No 7,722,898   Start Trial Y   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes 9,119,791   Start Trial   Start Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB RX Yes No 8,663,683   Start Trial Y   Start Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No 8,298,580   Start Trial Y   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes 9,370,525   Start Trial Y   Start Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No 9,549,940   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 200 mg ➤ Subscribe 2014-04-03
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2013-04-12
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, and 100 mg ➤ Subscribe 2014-05-12
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Medtronic
AstraZeneca
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.